Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades-Reference-Cited by-同舟云学术

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades

Published:2019-05-21 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Chen Hao,Chong Wei,Wu Qian,Yao Yueliang,Mao Min,Wang Xin

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference57 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med.,2015

2. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025;Escudier;Eur Urol.,2017

3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med.,2017

4. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med.,2016

5. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma;Van Allen;Science.,2015

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Pathogenic loss-of-function mutations in LRP1B are associated with poor survival in head and neck cancer patients;Journal of Stomatology, Oral and Maxillofacial Surgery;2024-07

3. The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer;MedComm;2024-06

4. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival;Cancer Medicine;2024-05

5. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer;JAMA Surgery;2024-05-01